[
    [
        {
            "time": "",
            "original_text": "3 2 股 获 高 管 增 持  华 大 基 因 获 增 持 金 额 最 多",
            "features": {
                "keywords": [
                    "高管增持",
                    "华大基因"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物技术",
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "3 2 股 获 高 管 增 持  华 大 基 因 获 增 持 金 额 最 多",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]